94P Neoadjuvant tislelizumab combined with (nab)-paclitaxel plus platinum-based chemotherapy for patients with stage IIA–IIIB squamous NSCLC: A real-world retrospective study

Immunotherapy combined with chemotherapy as neoadjuvant therapy has shown promising efficacy. Tislelizumab is an anti-PD-1 mAb approved in China for the treatment of first-line advanced squamous NSCLC combination chemotherapy. This study aimed to evaluate efficacy tislelizumab resectable stage IIA–IIIB a real-world setting. A retrospective analysis included patients (pts) (AJCC 8th) who received at Second Affiliated Hospital Medical School Zhejiang University between Apr 2020 and Oct 2022. The primary endpoints were major pathological response (MPR) rate complete (PCR) rate; secondary objective (ORR) by RECIST1.1, down-staging safety outcomes. 60 pts median age 55 (range 41–85) years, 98% males. 56 administrated nab-paclitaxel plus platinum-based chemotherapy, other 4 regime was paclitaxel instead nab-paclitaxel. All 2–3 cycles therapy. MPR PCR 81.67% (95%CI: 69.56-90.48) 41.67% 29.07-55.12) respectively. ORR, 75% 62.14-85.28), 38.3% 26.07-51.79), As 1 2022, follow-up time 20 (range: 4–29) months, 7 experienced recurrence, 5 them are non-MPR. For information, mild immune-related AEs such rash pneumonitis this analysis. revealed that (nab)-paclitaxel option IIA-IIIB NSCLC.